Chemomab Amends Merger Agreement to Set 10M-Share Post-Merger Structure
CMMB is trading near its 52-week low of $1.051 (13% above the low) on elevated volume (3.6× avg).
Summary
Chemomab filed an amendment to its Domestication Merger Agreement establishing a formula-based exchange ratio that results in 10 million shares outstanding post-merger, along with details on fractional shares, option substitution, and CVR issuance.
Key Events · M&A and Partnerships · CMMB
-
Exchange Ratio Formula Established
The Domestication Exchange Ratio is defined as the Chemomab Allocation divided by the sum of outstanding Chemomab Ordinary Shares and options, with the Chemomab Allocation equal to 10,000,000 multiplied by the Chemomab Allocation Percentage from the Merger Agreement.
-
Post-Merger Share Count Fixed
The Combined Company will have an aggregate of 10,000,000 shares outstanding immediately following the closing of the Merger.
-
Fractional Share Treatment
No fractional shares of Chemomab Parent Common Stock will be issued, and no cash will be paid for any fractional share eliminated by rounding.
-
Equity Award Substitution
Existing Chemomab options will be substituted with options to purchase Chemomab Parent Common Stock at an exercise price equal to the original exercise price divided by the Domestication Exchange Ratio, rounded up to the nearest whole cent.
Analysis · CMMB · Life Sciences
The amendment establishes the formula-based exchange ratio for the Domestication Merger, fixing the combined company at 10,000,000 shares outstanding after closing. It also clarifies fractional share treatment, equity award substitution mechanics, and CVR issuance. While the filing states the amendment is technical and does not change economic terms or ownership allocation, it provides concrete mechanics for how existing Chemomab shares and options convert into Chemomab Parent stock — details investors need to understand their post-merger position. The merger remains on track for Q4 2026 completion.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMMB was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.7M. The 52-week trading range was $1.05 to $3.58. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.